Church & Dwight CO Inc CHD
We take great care to ensure that the data presented and summarized in this overview for CHURCH & DWIGHT CO INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CHD
View all-
Vanguard Group Inc Valley Forge, PA31.8MShares$2.94 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY20.9MShares$1.93 Billion0.05% of portfolio
-
State Street Corp Boston, MA13.5MShares$1.24 Billion0.05% of portfolio
-
Capital International Investors Los Angeles, CA9.52MShares$878 Million0.16% of portfolio
-
Jpmorgan Chase & CO New York, NY7.13MShares$658 Million0.06% of portfolio
-
Terry Smith Fundsmith LLP | London, X06.82MShares$630 Million2.87% of portfolio
-
Geode Capital Management, LLC Boston, MA6.29MShares$580 Million0.04% of portfolio
-
Massachusetts Financial Services CO Boston, MA5.05MShares$466 Million0.16% of portfolio
-
Stifel Financial Corp St. Louis, MO4.28MShares$395 Million0.51% of portfolio
-
Morgan Stanley New York, NY3.95MShares$364 Million0.03% of portfolio
Latest Institutional Activity in CHD
Top Purchases
Top Sells
About CHD
Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.
Insider Transactions at CHD
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 12
2025
|
Richard A Dierker President and CEO |
BUY
Open market or private purchase
|
Direct |
5,470
+16.74%
|
$497,770
$91.57 P/Share
|
Aug 08
2025
|
Lee B Mc Chesney EVP, Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,409
+50.0%
|
$492,219
$91.38 P/Share
|
Aug 05
2025
|
Michael Read EVP, International |
BUY
Open market or private purchase
|
Direct |
2,000
+21.04%
|
$182,000
$91.27 P/Share
|
Jun 30
2025
|
Laurie Yoler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,249
+10.41%
|
$119,904
$96.11 P/Share
|
Jun 30
2025
|
Janet S. Vergis Director |
BUY
Grant, award, or other acquisition
|
Direct |
729
+4.09%
|
$69,984
$96.11 P/Share
|
Jun 30
2025
|
Penry W Price Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,457
+4.86%
|
$139,872
$96.11 P/Share
|
Jun 25
2025
|
Charles R Raup President US Domestic |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
$855,000
$95.25 P/Share
|
Jun 16
2025
|
Carlen Hooker EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,380
-96.06%
|
$625,240
$98.3 P/Share
|
Jun 16
2025
|
Carlen Hooker EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,380
+48.99%
|
$535,920
$84.85 P/Share
|
May 30
2025
|
Carlen Hooker EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,875
-92.99%
|
$1,163,750
$98.75 P/Share
|
May 30
2025
|
Carlen Hooker EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,875
+48.17%
|
$914,375
$77.88 P/Share
|
May 30
2025
|
Ravichandra Krishnamurty Saligram Director |
SELL
Open market or private sale
|
Indirect |
14,660
-51.61%
|
$1,451,340
$99.0 P/Share
|
May 30
2025
|
Ravichandra Krishnamurty Saligram Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
14,660
+34.04%
|
$601,060
$41.91 P/Share
|
May 29
2025
|
Carlen Hooker EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-91.97%
|
$294,000
$98.05 P/Share
|
May 29
2025
|
Carlen Hooker EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+47.91%
|
$219,000
$73.87 P/Share
|
May 14
2025
|
Richard A Dierker President and CEO |
BUY
Open market or private purchase
|
Direct |
5,384
+22.0%
|
$495,328
$92.8 P/Share
|
May 13
2025
|
Richard A Dierker President and CEO |
BUY
Open market or private purchase
|
Direct |
7,950
+20.91%
|
$747,300
$94.61 P/Share
|
May 09
2025
|
Michael Read EVP, International |
BUY
Open market or private purchase
|
Direct |
3,000
+35.27%
|
$276,000
$92.07 P/Share
|
May 08
2025
|
Penry W Price Director |
SELL
Open market or private sale
|
Direct |
14,660
-35.15%
|
$1,363,380
$93.13 P/Share
|
May 08
2025
|
Penry W Price Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,660
+26.01%
|
$601,060
$41.91 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 70.8K shares |
---|---|
Open market or private purchase | 31.1K shares |
Exercise of conversion of derivative security | 834K shares |
Payment of exercise price or tax liability | 9.19K shares |
---|---|
Open market or private sale | 843K shares |
Bona fide gift | 3.11K shares |